Carboplatin
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1989
- First approval year
- 1989
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Carboplatin
- Molecular weight
- 371.25
- Structure (SMILES)
- C1CC(C1)(C(=O)[O-])C(=O)[O-].N.[Pt+2].N
- carboplatin
- Carboplatin
- paraplatin
- Paraplatin
- 5fu paraplatin
- carboplatin
- Carboplatin
- CARBOPLATIN
- Carboplatin (area under the concentration curve [AUC] 6)
- Carboplatin (AUC 5)
- Carboplatin (Carboplatin Kabi)
- carboplatin (Cb)
- Carboplatin (dose level 1)
- Carboplatin (dose level 2)
- Carboplatin (Induction)
- Carboplatin (Investigator discretion)
- Carboplatin (not mandatory)
- Carboplatin (or cisplatin if carboplatin is not tolerated)
- carboplatin (palaplatin)
- Carboplatin (standard of care)
- CARBOPLATIN [EP IMPURITY]
- CARBOPLATIN [EP MONOGRAPH]
- CARBOPLATIN [HSDB]
- carboplatin [INN]
- CARBOPLATIN [JAN]
- CARBOPLATIN [MART.]
- CARBOPLATIN [MI]
- CARBOPLATIN [ORANGE BOOK]
- CARBOPLATIN [USAN]
And 51 more, listed on the interactive page.
- ATC classification codes
- L01XA02
Sources for recorded values
- CAS registry numbers
- 41575-94-4
- ChEMBL ID
- CHEMBL1351
- InChIKey
- OLESAACUTLOWQZ-UHFFFAOYSA-L
- PubChem compound IDs
- 10339178
- RxNorm IDs (RxCUI)
- 40048
- FDA ingredient codes (UNII)
- BG3F62OND5
- Applicant
- AVYXA HOLDINGS
- Approval date
- 8 Aug 2025
- Application number
- NDA219921
- Patents
- 1
- Designations
- 2
- Earliest recorded loss of exclusivity
- 1 Apr 2045
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- Pharmacology name
- carboplatin
- Type
- Inorganic
- Drug name stem
- -platin
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
Mechanisms of action
- Mechanism
- DNA inhibitor
- Action type
- Inhibitor
- Target
- DNA
- Condition
- Lymphoma, Follicular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000096
- Subject identifier
- D008224
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Hodgkin Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000196
- Subject identifier
- D011471
- Condition
- Myelodysplastic Syndromes
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000198
- Subject identifier
- D009190
- Condition
- Squamous Cell Carcinoma of Head and Neck
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000199
- Subject identifier
- D000077195
- Condition
- Neoplasms, Plasma Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000200
- Subject identifier
- D054219
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Adenocarcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000228
- Subject identifier
- D000230
- Condition
- Astrocytoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000272
- Subject identifier
- D001254
- Condition
- Breast Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000305
- Subject identifier
- D001943
- Condition
- Adenocarcinoma, Bronchiolo-Alveolar
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000308
- Subject identifier
- D002282
- Condition
- Burkitt Lymphoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000309
- Subject identifier
- D002051
- Condition
- Carcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000313
- Subject identifier
- D002277
- Condition
- Melanoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000389
- Subject identifier
- D008545
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Carcinoma, Intraductal, Noninfiltrating
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000432
- Subject identifier
- D002285
- Condition
- Carcinoma, Endometrioid
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000466
- Subject identifier
- D018269
- Condition
- Adenocarcinoma, Follicular
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000501
- Subject identifier
- D018263
- Condition
- Ganglioneuroblastoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000502
- Subject identifier
- D018305
- Condition
- Neoplasms, Germ Cell and Embryonal
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000514
- Subject identifier
- D009373
- Condition
- Glioblastoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000519
- Subject identifier
- D005909
- Condition
- Insulinoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000549
- Subject identifier
- D007340
- Condition
- Leiomyosarcoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000564
- Subject identifier
- D007890
And 172 more, listed on the interactive page.
- Condition identifier
- EFO_0000181
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000183
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000196
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000305
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000313
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000389
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000403
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000432
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000519
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000565
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000571
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000588
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000621
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000637
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000673
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000691
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000702
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000707
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000708
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000756
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000770
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001061
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001075
And 325 more, listed on the interactive page.
- Warning
- Black Box Warning
- Effect
- cardiotoxicity
- Warning
- Black Box Warning
- Effect
- gastrointestinal toxicity
- Warning
- Black Box Warning
- Effect
- hematological toxicity
- Warning
- Black Box Warning
- Effect
- immune system toxicity
- Warning
- Black Box Warning
- Effect
- nephrotoxicity
- Warning
- Black Box Warning
- Effect
- cardiotoxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- gastrointestinal toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- hematological toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- immune system toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- nephrotoxicity
- Country
- United States
- Event
- acute myeloid leukaemia
- Reports
- 331
- Reporting signal score
- 507.106
- Event
- anaemia
- Reports
- 3,624
- Reporting signal score
- 2,305.83
- Event
- bone marrow failure
- Reports
- 1,004
- Reporting signal score
- 1,203.88
- Event
- dehydration
- Reports
- 2,224
- Reporting signal score
- 1,521.78
- Event
- disease progression
- Reports
- 2,004
- Reporting signal score
- 1,625.01
- Event
- febrile neutropenia
- Reports
- 4,014
- Reporting signal score
- 6,553.87
- Event
- haematotoxicity
- Reports
- 698
- Reporting signal score
- 1,209.13
- Event
- hypokalaemia
- Reports
- 1,201
- Reporting signal score
- 994.497
- Event
- hypomagnesaemia
- Reports
- 632
- Reporting signal score
- 785.586
- Event
- injection site pain
- Reports
- 9
- Reporting signal score
- 782.398
- Event
- leukopenia
- Reports
- 1,493
- Reporting signal score
- 1,298.38
- Event
- malignant neoplasm progression
- Reports
- 1,847
- Reporting signal score
- 1,955.69
- Event
- mucosal inflammation
- Reports
- 1,582
- Reporting signal score
- 2,365.86
- Event
- myelosuppression
- Reports
- 760
- Reporting signal score
- 1,266.3
- Event
- nausea
- Reports
- 4,962
- Reporting signal score
- 828.225
- Event
- neutropenia
- Reports
- 4,293
- Reporting signal score
- 4,326.68
- Event
- neutropenic sepsis
- Reports
- 541
- Reporting signal score
- 1,007.89
- Event
- neutrophil count decreased
- Reports
- 1,380
- Reporting signal score
- 1,531.79
- Event
- pancytopenia
- Reports
- 1,735
- Reporting signal score
- 1,789.88
- Event
- thrombocytopenia
- Reports
- 3,208
- Reporting signal score
- 2,730.95
- Event
- vomiting
- Reports
- 3,986
- Reporting signal score
- 1,097.84
- NCT00001502
- NCT00002944
- NCT00003141
- NCT00003203
- NCT00027846
- NCT00078988
- NCT00085098
- NCT00528437
- NCT02253212
- NCT00180791
- NCT00336024
- NCT00392327
- NCT00749723
- NCT01857453
- NCT02025881
- NCT05535166
- NCT01445119
- NCT03149575
- NCT00002474
- NCT00002477
- NCT00002600
- NCT00002819
- NCT00002894
- NCT00003064
- NCT00003136
And 1,808 more, listed on the interactive page.
- Dose
- 360 mg/m2
- Route
- Intravenous
- How often
- Every 4 weeks
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Heavy atoms
- 13
- Molecular formula
- C6H12N2O4Pt
- Monoisotopic mass
- 371.044501
- Natural product
- No
- 0703-4239
- 0703-4244
- 0703-4246
- 0703-4248
- 16729-295
- 54288-164
- 54288-165
- 54288-166
- 54288-167
- 55150-333
- 55150-334
- 55150-335
- 55150-386
- 61703-150
- 61703-262
- 61703-339
- 61703-360
- 61703-600
- 63323-172
- 68083-190
- 68083-191
- 68083-192
- 68083-193
- 69339-364
- 69339-365
And 9 more, listed on the interactive page.
- Recorded assays
- 2
- Active assays
- 0
- Antineoplastic Agents
- Cross-Linking Reagents
Liver toxicity assay
- Median
- 36,100
- Mean
- 36,100
- Minimum
- 36,100
- Maximum
- 36,100
- Unit
- nM
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- IC50
Related records
Trials (3,038)
- 'ADVANCE' (A Pilot Trial)
- (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
- (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
- (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
- (VELA) Study of BLU-222 in Advanced Solid Tumors
- 131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma
- 4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC
- 6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors
- 9-ING-41 in Patients With Advanced Cancers
- 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
- 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
- 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
- A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC
- A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer
- A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer
- A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
- A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
- A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)
- A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Approved for (6)
- Cancer
- Malignant epithelial tumor of ovary
- Neoplasm
- Ovarian cancer
- Ovarian carcinoma
- Ovarian neoplasm
In development for (189)
- Acute myeloid leukemia Phase 2
- Adenocarcinoma Phase 2
- Adrenal cortex carcinoma Phase 1
- Adult T-cell leukemia/lymphoma Phase 3
- Anaplastic astrocytoma Phase 3
- Anaplastic ependymoma Phase 3
- Anaplastic large cell lymphoma Phase 1
- Anaplastic oligodendroglioma Phase 2
- Anemia Phase 3
- Anus cancer Phase 1
- Appendix carcinoma Phase 1
- Astrocytoma (excluding glioblastoma) Phase 3
- B-cell non-Hodgkin lymphoma Phase 2
- Bile duct cancer Phase 2
- Biliary tract cancer Phase 3
- Bone cancer Phase 2
- Bone neoplasm Phase 2
- Brain cancer Phase 3
- Brain neoplasm Phase 3
- Brainstem neoplasm Phase 2
Other linked conditions (2)
- Lip and oral cavity carcinoma
- Tongue neoplasm